多学科团队减少 2 型糖尿病患者大血管和微血管并发症的成本节约:预测模型。

IF 2.1 Q3 HEALTH CARE SCIENCES & SERVICES
ClinicoEconomics and Outcomes Research Pub Date : 2024-04-04 eCollection Date: 2024-01-01 DOI:10.2147/CEOR.S451739
Abdulmajeed Alshowair, Saleh Altamimi, Faisal A Alruhaimi, Saad Alshahrani, Fatima Alsuwailem, Mona Alkhaldi, Haiam Abdalla, Fahad Hamad Alkhuraiji, Montaser Saad Alaqeel, Salman Sulaiman Almureef, Salman Alhawasy, Amro Abdel-Azeem
{"title":"多学科团队减少 2 型糖尿病患者大血管和微血管并发症的成本节约:预测模型。","authors":"Abdulmajeed Alshowair, Saleh Altamimi, Faisal A Alruhaimi, Saad Alshahrani, Fatima Alsuwailem, Mona Alkhaldi, Haiam Abdalla, Fahad Hamad Alkhuraiji, Montaser Saad Alaqeel, Salman Sulaiman Almureef, Salman Alhawasy, Amro Abdel-Azeem","doi":"10.2147/CEOR.S451739","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to predict the expected cost savings associated with implementing a multidisciplinary team (MDT) approach to reduce macrovascular and microvascular complications among patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>This economic evaluation study was conducted in Riyadh First Health Cluster, Saudi Arabia as a predictive model conceptualized by the authors based on models used in previous studies, particularly the CORE Diabetes Model. Our model was designed based on 1) the level of glycemic control among 24,755 T2DM patients served by MDTs; 2) the expected incidence of diabetes-related complications without intervention; 3) the predicted risk reduction of developing diabetes-related complications with MDTs. Costs of complications and cost savings were then calculated and expressed as mean incremental annual cost savings adjusted for a 1% reduction in HbA1c, and a 10 mmHg reduction in systolic blood pressure (SBP).</p><p><strong>Results: </strong>Along with the expected reduction in all diabetes-related complications, the average incremental cost savings per diabetic patient is predicted to be ($38,878) with approximately ($11,108) in the year of complication onset and ($27,770) over the subsequent post-index 10-years. On adjustment of cost savings, the average incremental cost savings are predicted to be ($22,869) for each 1% reduction in HbA1c per diabetic patient and ($27,770) for every 10 mmHg reduction in SBP per diabetic patient.</p><p><strong>Conclusion: </strong>MDT as a model of care is effective in glycemic control among T2DM patients with a predicted significant reduction of all diabetes-related complications and in turn, a predicted significant cost savings.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001564/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cost-Savings Associated with Multi-Disciplinary Team Approach for Reducing Macrovascular and Microvascular Complications in Patients with Type 2 Diabetes: A Predictive Model.\",\"authors\":\"Abdulmajeed Alshowair, Saleh Altamimi, Faisal A Alruhaimi, Saad Alshahrani, Fatima Alsuwailem, Mona Alkhaldi, Haiam Abdalla, Fahad Hamad Alkhuraiji, Montaser Saad Alaqeel, Salman Sulaiman Almureef, Salman Alhawasy, Amro Abdel-Azeem\",\"doi\":\"10.2147/CEOR.S451739\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aims to predict the expected cost savings associated with implementing a multidisciplinary team (MDT) approach to reduce macrovascular and microvascular complications among patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>This economic evaluation study was conducted in Riyadh First Health Cluster, Saudi Arabia as a predictive model conceptualized by the authors based on models used in previous studies, particularly the CORE Diabetes Model. Our model was designed based on 1) the level of glycemic control among 24,755 T2DM patients served by MDTs; 2) the expected incidence of diabetes-related complications without intervention; 3) the predicted risk reduction of developing diabetes-related complications with MDTs. Costs of complications and cost savings were then calculated and expressed as mean incremental annual cost savings adjusted for a 1% reduction in HbA1c, and a 10 mmHg reduction in systolic blood pressure (SBP).</p><p><strong>Results: </strong>Along with the expected reduction in all diabetes-related complications, the average incremental cost savings per diabetic patient is predicted to be ($38,878) with approximately ($11,108) in the year of complication onset and ($27,770) over the subsequent post-index 10-years. On adjustment of cost savings, the average incremental cost savings are predicted to be ($22,869) for each 1% reduction in HbA1c per diabetic patient and ($27,770) for every 10 mmHg reduction in SBP per diabetic patient.</p><p><strong>Conclusion: </strong>MDT as a model of care is effective in glycemic control among T2DM patients with a predicted significant reduction of all diabetes-related complications and in turn, a predicted significant cost savings.</p>\",\"PeriodicalId\":47313,\"journal\":{\"name\":\"ClinicoEconomics and Outcomes Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001564/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ClinicoEconomics and Outcomes Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/CEOR.S451739\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ClinicoEconomics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CEOR.S451739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在预测采用多学科团队(MDT)方法减少 2 型糖尿病(T2DM)患者的大血管和微血管并发症预计可节约的成本:这项经济评估研究在沙特阿拉伯利雅得第一健康集群进行,是作者根据以往研究中使用的模型(尤其是 CORE 糖尿病模型)构思的一个预测模型。我们的模型是根据以下几点设计的:1)接受 MDT 服务的 24,755 名 T2DM 患者的血糖控制水平;2)在不采取干预措施的情况下,糖尿病相关并发症的预期发病率;3)采用 MDT 降低糖尿病相关并发症发病风险的预测值。然后计算并发症的成本和节约的成本,并将其表示为根据 HbA1c 下降 1%、收缩压 (SBP) 下降 10 mmHg 调整后的平均每年节约成本增量:随着所有糖尿病相关并发症的预期减少,每名糖尿病患者的平均增量成本节约额预计为(38878 美元),其中并发症发生当年约为(11108 美元),随后指数后 10 年内约为(27770 美元)。在对节省的成本进行调整后,预计每位糖尿病患者的 HbA1c 每降低 1%,平均可节省增量成本(22,869 美元);每位糖尿病患者的 SBP 每降低 10 mmHg,平均可节省增量成本(27,770 美元):MDT作为一种护理模式,能有效控制T2DM患者的血糖,预计能显著减少所有与糖尿病相关的并发症,进而大幅节约成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cost-Savings Associated with Multi-Disciplinary Team Approach for Reducing Macrovascular and Microvascular Complications in Patients with Type 2 Diabetes: A Predictive Model.

Purpose: This study aims to predict the expected cost savings associated with implementing a multidisciplinary team (MDT) approach to reduce macrovascular and microvascular complications among patients with type 2 diabetes mellitus (T2DM).

Methods: This economic evaluation study was conducted in Riyadh First Health Cluster, Saudi Arabia as a predictive model conceptualized by the authors based on models used in previous studies, particularly the CORE Diabetes Model. Our model was designed based on 1) the level of glycemic control among 24,755 T2DM patients served by MDTs; 2) the expected incidence of diabetes-related complications without intervention; 3) the predicted risk reduction of developing diabetes-related complications with MDTs. Costs of complications and cost savings were then calculated and expressed as mean incremental annual cost savings adjusted for a 1% reduction in HbA1c, and a 10 mmHg reduction in systolic blood pressure (SBP).

Results: Along with the expected reduction in all diabetes-related complications, the average incremental cost savings per diabetic patient is predicted to be ($38,878) with approximately ($11,108) in the year of complication onset and ($27,770) over the subsequent post-index 10-years. On adjustment of cost savings, the average incremental cost savings are predicted to be ($22,869) for each 1% reduction in HbA1c per diabetic patient and ($27,770) for every 10 mmHg reduction in SBP per diabetic patient.

Conclusion: MDT as a model of care is effective in glycemic control among T2DM patients with a predicted significant reduction of all diabetes-related complications and in turn, a predicted significant cost savings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ClinicoEconomics and Outcomes Research
ClinicoEconomics and Outcomes Research HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.70
自引率
0.00%
发文量
83
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信